The relationship between bone marrow activity detected on PET / CT and prognosis in patients with lymphoma

2020 ◽  
Vol 27 (2) ◽  
pp. 461
Author(s):  
Ahmet Yanarates ◽  
Emine Budak
Keyword(s):  
Bone Marrow ◽  
Pet Ct ◽  
The Relationship ◽  
Marrow Activity

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5360-5360
Author(s):  
Lars C. Gormsen ◽  
Cecilia Wassberg ◽  
Daniel Molin ◽  
Peter Kamper ◽  
Gunilla Enblad ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Logistic Regression ◽  
Independent Predictor ◽  
Bone Lesions ◽  
Classical Hodgkin Lymphoma ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
The Relationship ◽  
Initial Staging

Abstract Background: 18F-FDG PET/CT is recommended in the initial staging of patients with classical Hodgkin lymphoma (cHL). Whereas focal 18F-FDG uptake in the skeleton is considered to represent bone involvement, it is still unclear whether diffusely increased 18F-FDG bone marrow uptake (BMU) indicates lymphoma infiltration or merely reflects a state of general inflammation. This retrospective study was therefore performed to study the relationship between pre-therapeutic (PET0) 18F-FDG BMU and the presence of focal bone lesions. Methods: A total of 139 patients (median age 44, range 8-83) referred to PET/CT between 2008 and 2014 for HL staging were included. All PET0 and post-therapeutic (PET2) images were reviewed and evidence of focal bone lesions was recorded (unifocal: ≤2 lesions, multifocal: >2 lesions). In addition, 18F-FDG uptake (SUVmax) was semiquantitatively measured in the vertebral bone marrow (SUVvertebra) and in the right lobe of the liver (SUVliver). BMU was calculated as SUVvertebra/SUVliver. The relationship between focal bone lesions on PET0 and BMU as well as age was subsequently analysed by logistic regression. Results: In total 30/139 (22 %) patients had focal bone lesions at initial staging (10 unifocal, 20 multifocal). BMU at initial presentation was generally increased in all patients when compared with the post-therapeutic PET/CT (PET0: 1.22 +/- 0.03 vs. PET2: 0.95 +/- 0.03, p<0.001). In a logistic regression model diffusely increased BMU at PET0 (p=0.01) as well as age (p=0.01) were both independent predictors of focal bone lesions. Conclusion: Diffusely increased 18F-FDG uptake is an independent predictor of skeletal bone lesions in patients with HL. Evidence of increased BMU might be evaluated as an additional outcome predictor in the pre-therapeutic risk assessment of patients with HL. With the purpose of validating these findings, we will analyze an independent cohort of Swedish cHL patients and joined data from both cohorts will be presented at the meeting. Disclosures No relevant conflicts of interest to declare.

SERIAL STUDY OF BONE MARROW IN HEMOLYTIC DISEASE OF THE NEWBORN (ERYTHROBLASTOSIS FETALIS)

PEDIATRICS ◽  
1959 ◽  
Vol 23 (2) ◽  
pp. 314-322
Author(s):  
Hugh C. Dillon ◽  
William Krivit
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Exchange Transfusion ◽  
Rare Occurrence ◽  
Review Of The Literature ◽  
Hemolytic Disease ◽  
Cell Production ◽  
Cell Destruction ◽  
The Relationship ◽  
Marrow Activity

Fourteen infants with erythroblastosis fetalis were studied with particular reference to bone marrow activity and its relation to anemia in the infants. Serial studies of the marrow were done in 12 of the 14 infants, and single specimens were examined in two infants. No attempt is made to define the etiology or pathogenesis of the anemia of erythroblastosis fetalis. The purpose of this study was to determine the relationship between degree of anemia and normoblastic activity of bone marrow, as ascertained by morphologic techniques. On the basis of a review of the literature and the experience with this series of infants, true "aregenerative anemia" appears to be a rare occurrence. Indeed, to suggest that the anemia of erythroblastosis is commonly due to a cessation of erythropoiesis seems totally unjustified, because these infants show hyperplasia of the marrow which is analogous to that seen in other compensated hemolytic anemias. Human and Sturgeon have stated, and the authors agree, that a relative hypoplasia may occur as cell destruction exceeds cell production. This does not necessarily imply marrow failure or an "aregenerative state," but it may indicate that the balance can be in favor of blood destruction and an anemia of some degree is the result. In a previous report, infants after exchange transfusion did show excessive destruction of donor erythrocytes. The rate of destruction of Rh-negative cells in erythroblastosis fetalis was twice that of normal. Some of the cases reported in the literature as "aregenerative anemia" lack adequate marrow studies and cannot be accepted as well-documented. It should be emphasized that it may be unwise to conjecture about activity of the bone marrow from reticulocyte studies of the peripheral blood alone. In this series, the percentage of normoblats in the bone marrow was increased in proportion to the degree of anemia.

Visual and quantitative approach to bone marrow foci of increased glucose uptake on PET/CT in a case of aplastic anaemia

2010 ◽  
Vol 49 (02) ◽  
pp. N10-N12 ◽  
Author(s):  
F. Cicone ◽  
M. Stalder ◽  
D. Geiger ◽  
A. Cairoli ◽  
A. Bischof Delaloye ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Glucose Uptake ◽  
Aplastic Anaemia ◽  
Quantitative Approach ◽  
Pet Ct

PET/CT WITH 68GA-PSMA-11 IN DETECTION OF PRIMARY TUMOR AND RECURRENCE OF PROSTATE CANCER

2018 ◽  
Vol 64 (6) ◽  
pp. 799-804
Author(s):  
Darya Ryzhkova ◽  
M. Poyda
Keyword(s):  
Prostate Cancer ◽  
Primary Tumor ◽  
Biochemical Recurrence ◽  
Whole Body ◽  
Negative Results ◽  
Primary Prostate Cancer ◽  
Pet Ct ◽  
The Relationship ◽  
Positive Results ◽  
T Category

Purpose: To study the diagnostic value of PET-CT with 68Ga-PSMA-11 in the diagnosis of a primary prostate cancer, preoperative staging, and the detection of recurrence of prostate cancer (PCa). Methods: 28 patients aged 64.7 ± 8.74 years were included. 10 patients primary prostate cancer, and 18 patients with biochemical recurrence of the disease after radical treatment were examined. All patients underwent PET-CT with 68Ga-PSMA-11 according the whole body protocol. Interpretation of images was performed visually and quantitatively by calculation of SUL max. Results: High focal or diffuse 68Ga-PSMA-11 uptake was found in prostate parenchyma in patients with primary prostate cancer. Additionally metastases in regional lymph nodes were diagnosed in 4 patients and bone metastases were found in one patient. The correlation between 68Ga-PSMA-11 uptake level and Gleason index in the primary tumor (R Spearmen = 0.25, p = 0.57) was not observed. PET-positive results were obtained in 14 patients and PET-negative results in 4 patients with biochemical recurrence of PCa. The relationship between the frequency of PET-positive results and Gleason index was not revealed (R Spearmen = 0.2, p = 0.39). We found a weak but significant correlation between the frequency of PET-positive results and the prostate tumor stage according to the T category (R Spearmen = 0.49, p = 0.049). In patients with low values of PSA (less than 1.0 ng/ml) in 4 out of 9 cases, PET-negative results were obtained. In patients with PSA level more than 1.0 ng/ml PET-positive results were obtained in all cases. Conclusions: PET/CT with 68Ga-PSMA-11 allows to diagnose the primary prostate cancer, to establish the stage of the disease in categories N and M, and also to determine the localization and dissemination of the tumor in patients with biochemical recurrence of prostate cancer. The relationship between 68Ga-PSMA-11 uptake in primary tumor and Gleason index was not found. The probability of obtaining PET-positive results in cases of biochemical recurrence is affected by a PSA level above 1 ng/ml and a high stage of the disease according to the T category (T3-T4).

scholarly journals Artificial intelligence could alert for focal skeleton/bone marrow uptake in Hodgkin’s lymphoma patients staged with FDG-PET/CT

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
May Sadik ◽  
Jesús López-Urdaneta ◽  
Johannes Ulén ◽  
Olof Enqvist ◽  
Armin Krupic ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Bone Marrow ◽  
Fdg Pet ◽  
Test Group ◽  
Observer Agreement ◽  
Hodgkin's Lymphoma ◽  
Bone Marrow Uptake ◽  
Focal Uptake ◽  
Pet Ct ◽  
Fdg Pet Ct

AbstractTo develop an artificial intelligence (AI)-based method for the detection of focal skeleton/bone marrow uptake (BMU) in patients with Hodgkin’s lymphoma (HL) undergoing staging with FDG-PET/CT. The results of the AI in a separate test group were compared to the interpretations of independent physicians. The skeleton and bone marrow were segmented using a convolutional neural network. The training of AI was based on 153 un-treated patients. Bone uptake significantly higher than the mean BMU was marked as abnormal, and an index, based on the total squared abnormal uptake, was computed to identify the focal uptake. Patients with an index above a predefined threshold were interpreted as having focal uptake. As the test group, 48 un-treated patients who had undergone a staging FDG-PET/CT between 2017–2018 with biopsy-proven HL were retrospectively included. Ten physicians classified the 48 cases regarding focal skeleton/BMU. The majority of the physicians agreed with the AI in 39/48 cases (81%) regarding focal skeleton/bone marrow involvement. Inter-observer agreement between the physicians was moderate, Kappa 0.51 (range 0.25–0.80). An AI-based method can be developed to highlight suspicious focal skeleton/BMU in HL patients staged with FDG-PET/CT. Inter-observer agreement regarding focal BMU is moderate among nuclear medicine physicians.

scholarly journals Characteristics and Clinical Value of 18F-FDG PET/CT in the Management of Adult-Onset Still’s Disease: 35 Cases

2021 ◽  
Vol 10 (11) ◽  
pp. 2489
Author(s):  
Josselin Brisset ◽  
Yvan Jamilloux ◽  
Stephanie Dumonteil ◽  
Guillaume Lades ◽  
Martin Killian ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lymph Node ◽  
Differential Diagnoses ◽  
Adult Onset Still’S Disease ◽  
Still’S Disease ◽  
Clinical Value ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Adult Onset Still's Disease

While the diagnosis of adult-onset Still’s disease (AOSD) involves the exclusion of differential diagnoses, the characteristics and value of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography coupled with CT (PET/CT) in the management of AOSD remain poorly known. Our retrospective study included patients from four centers, fulfilling Yamaguchi or Fautrel criteria, who underwent a PET/CT during an active AOSD. Thirty-five patients were included. At the time of PET/CT, the Yamaguchi criteria were met in 23 of 29 evaluable cases. PET/CT showed bone marrow (74.3%), lymph node (74.3%), and splenic (48.6%) FDG uptake. Despite arthralgia or arthritis in most patients, joints were rarely the sites of 18F-FDG accumulation. The spatial distribution of 18F-FDG uptake was nonspecific, and its intensity could be similar to malignant disease. Lymph node or bone marrow biopsy was performed after PET/CT in 20 patients (57.1%). The intensity of bone marrow; splenic and lymph node hypermetabolism appeared to be correlated with disease activity. Abnormal PET/CT in the cervical lymph nodes and age ≥ 60 years seemed to be predictive factors for monocyclic evolution. The clinical value of PET/CT is not in direct diagnosis; but as an aid in excluding differential diagnoses by searching for their scintigraphic features and guiding biopsy.

scholarly journals ANISOCYTOSIS IS ASSOCIATED WITH REDUCED BONE MARROW ACTIVITY ASSESSED BY POSITRON EMISSION TOMOGRAPHY

2021 ◽  
Vol 77 (18) ◽  
pp. 1406
Author(s):  
Scott Janus ◽  
Jamal Hajjari ◽  
Anshul Badhwar ◽  
Corrilynn O. Hileman ◽  
Sadeer Al-Kindi ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Emission Tomography ◽  
Positron Emission ◽  
Marrow Activity

scholarly journals The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1575
Author(s):  
Lucia Zanoni ◽  
Riccardo Mei ◽  
Lorenzo Bianchi ◽  
Francesca Giunchi ◽  
Lorenzo Maltoni ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Malignant Lesion ◽  
Lesion Detection ◽  
Histopathological Analysis ◽  
Choline Pet ◽  
Primary Prostate Cancer ◽  
Pet Ct

The primary aim of the study was to evaluate the role of [18F]Fluciclovine PET/CT in the characterization of intra-prostatic lesions in high-risk primary PCa patients eligible for radical prostatectomy, in comparison with conventional [11C]Choline PET/CT and validated by prostatectomy pathologic examination. Secondary aims were to determine the performance of PET semi-quantitative parameters (SUVmax; target-to-background ratios [TBRs], using abdominal aorta, bone marrow and liver as backgrounds) for malignant lesion detection (and best cut-off values) and to search predictive factors of malignancy. A six sextants prostate template was created and used by PET readers and pathologists for data comparison and validation. PET visual and semi-quantitative analyses were performed: for instance, patient-based, blinded to histopathology; subsequently lesion-based, un-blinded, according to the pathology reference template. Among 19 patients included (mean age 63 years, 89% high and 11% very-high-risk, mean PSA 9.15 ng/mL), 45 malignant and 31 benign lesions were found and 19 healthy areas were selected (n = 95). For both tracers, the location of the “blinded” prostate SUVmax matched with the lobe of the lesion with the highest pGS in 17/19 cases (89%). There was direct correlation between [18F]Fluciclovine uptake values and pISUP. Overall, lesion-based (n = 95), the performance of PET semiquantitative parameters, with either [18F]Fluciclovine or [11C]Choline, in detecting either malignant/ISUP2-5/ISUP4-5 PCa lesions, was moderate and similar (AUCs ≥ 0.70) but still inadequate (AUCs ≤ 0.81) as a standalone staging procedure. A [18F]Fluciclovine TBR-L3 ≥ 1.5 would depict a clinical significant lesion with a sensitivity and specificity of 85% and 68% respectively; whereas a SUVmax cut-off value of 4 would be able to identify a ISUP 4-5 lesion in all cases (sensitivity 100%), although with low specificity (52%). TBRs (especially with threshold significantly higher than aorta and slightly higher than bone marrow), may be complementary to implement malignancy targeting.

Sign in / Sign up

Export Citation Format

Share Document